CellaVision AB (SE:CEVI)
:CEVI
Want to see SE:CEVI full AI Analyst Report?
Top Page
CellaVision AB
(CEVI)
Select Model
Select Model
Rating:67Neutral
Price Target:
kr159.00
▼(-1.24% Downside)
Action:Downgraded
Date:05/25/26
The score is primarily supported by strong financial quality—especially the conservative balance sheet and resilient margins—but is held back by weak technicals (price below all key moving averages, negative MACD) and a high P/E that makes the stock less forgiving if growth remains soft.
Positive Factors
Conservative balance sheet
Extremely low leverage and large equity provide durable financial flexibility. This conservatism supports continued R&D, service investment and resilience through reimbursement or demand cycles, reducing bankruptcy risk and enabling opportunistic M&A or share returns over the next several quarters.
Negative Factors
Recent revenue decline
A falling TTM top line signals weaker demand or installation cadence for capital instruments. If installations and new account penetration remain soft, recurring revenue growth may slow, making it harder to sustain long-term EPS growth and justify ongoing R&D or commercial investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage and large equity provide durable financial flexibility. This conservatism supports continued R&D, service investment and resilience through reimbursement or demand cycles, reducing bankruptcy risk and enabling opportunistic M&A or share returns over the next several quarters.
Read all positive factors
CellaVision AB (CEVI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr3.50B
Dividend Yield1.61%
Average Volume (3M)36.08K
Price to Earnings (P/E)25.5
Beta (1Y)0.79
Revenue Growth-2.32%
EPS Growth-11.87%
CountrySE
Employees228
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)5.62
Shares Outstanding23,851,547
10 Day Avg. Volume30,505
30 Day Avg. Volume36,083
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.17
Revenue Forecast (FY)kr823.52M
CellaVision AB Business Overview & Revenue Model
Company Description
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a g...
How the Company Makes Money
CellaVision makes money primarily by selling laboratory instrumentation and generating recurring revenue from software and related offerings. Key revenue streams include: (1) Instrument/system sales: upfront revenue from selling digital cell morph...
CellaVision AB Earnings Call Summary
Earnings Call Date:Feb 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 17, 2026
Earnings Call Sentiment Positive
The call presents a broadly positive operational and financial picture: solid revenue and organic growth, a strong EBITDA margin above target, record Americas performance, important strategic progress (bone marrow CE Mark, software validation, DI-60 throughput improvements), a healthy cash position and a proposed dividend increase. Offsetting factors include a weak APAC quarter driven by comparables and tender timing, softness in reagents/software mix that pressured Q4 gross margin, FX headwinds, and near-term uncertainty on revenue ramp from new product launches (bone marrow and U.S. methanol-free reagents). Overall these negatives appear manageable against the company’s clear commercial momentum and strategic milestones.Positive Updates
Q4 Revenue and Organic Growth
Net sales for Q4 increased 5.6% to SEK 197 million, corresponding to organic growth of 12.2% after an FX headwind of -6.6%.
Negative Updates
APAC Softness and Large Comparable Impact
APAC Q4 revenue SEK 28 million representing an organic decline of ~-40% quarter-on-quarter, primarily driven by a very strong comparable period last year (one-off tender in New South Wales) and shipment phasing.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Revenue and Organic Growth
Net sales for Q4 increased 5.6% to SEK 197 million, corresponding to organic growth of 12.2% after an FX headwind of -6.6%.
Read all positive updates
Company Guidance
Management gave no formal numeric 2026 revenue guide but outlined timing and drivers: Q4 revenue SEK 197m (+5.6%; organic +12.2% after FX -6.6%), Q4 gross margin 67% (FY 68%), operating expenses 39%, EBITDA SEK 65m (33%, above 30% target), Q4 R&D SEK 37m (19% of sales) with SEK 15m capitalized (FY capitalized R&D SEK 67m), operating cash flow SEK 51m and total Q4 cash flow SEK 30m, year‑end cash SEK 188m and FY revenue SEK 759m (organic +9%). Looking ahead they expect continued Americas momentum (Q4 Americas SEK 90m; organic ~50–58%) and healthy order intake/shipments into H1 2026, rollout of software 7.2 bundled with DI‑60 (instrument price increases planned but software not separately charged), CE‑marked bone‑marrow application to start generating revenue in H2 2026 (targeting Q4), methanol‑free reagents to be launched/scaled in 2026 with limited 2026 contribution, sustained high R&D investment in 2026 with a similar capitalization rate and some near‑term gross‑margin headwinds from FX, product mix and depreciation (management noted roughly a ~1 percentage‑point margin impact from starting depreciation).CellaVision AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
73
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 730.59M | 758.97M | 723.22M | 677.29M | 639.34M | 565.55M |
| Gross Profit | 496.66M | 519.88M | 487.07M | 463.04M | 438.32M | 392.30M |
| EBITDA | 215.14M | 237.28M | 219.75M | 207.25M | 198.36M | 193.60M |
| Net Income | 134.07M | 153.08M | 140.72M | 130.31M | 118.33M | 125.34M |
Balance Sheet | ||||||
| Total Assets | 1.13B | 1.09B | 1.01B | 928.71M | 891.75M | 825.21M |
| Cash, Cash Equivalents and Short-Term Investments | 230.22M | 188.22M | 149.43M | 121.64M | 108.05M | 130.29M |
| Total Debt | 22.43M | 25.65M | 26.85M | 64.70M | 102.50M | 136.65M |
| Total Liabilities | 220.53M | 207.31M | 196.16M | 212.32M | 250.12M | 281.93M |
| Stockholders Equity | 914.25M | 887.58M | 815.73M | 716.39M | 641.63M | 543.28M |
Cash Flow | ||||||
| Free Cash Flow | 119.22M | 181.72M | 120.69M | 109.96M | 67.85M | 75.41M |
| Operating Cash Flow | 201.54M | 200.53M | 198.44M | 196.44M | 137.28M | 159.72M |
| Investing Cash Flow | -81.49M | -86.16M | -76.01M | -85.53M | -70.01M | -84.34M |
| Financing Cash Flow | -75.15M | -74.59M | -95.09M | -97.04M | -90.41M | -48.48M |
CellaVision AB Technical Analysis
Positive
161.00
Price Trends
131.66
Positive
139.53
Positive
152.10
Negative
Market Momentum
2.08
Negative
75.40
Negative
87.81
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CEVI, the sentiment is Positive. The current price of 161 is above the 20-day moving average (MA) of 125.63, above the 50-day MA of 131.66, and above the 200-day MA of 152.10, indicating a neutral trend. The MACD of 2.08 indicates Negative momentum. The RSI at 75.40 is Negative, neither overbought nor oversold. The STOCH value of 87.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CEVI.
CellaVision AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | kr8.52B | 111.31 | 1.20% | ― | -2.39% | -46.09% | |
67 Neutral | kr3.50B | 25.55 | 17.89% | 1.61% | -2.32% | -11.87% | |
64 Neutral | kr1.25B | 41.99 | 6.93% | ― | -8.92% | -8.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr835.42M | -20.48 | -4.42% | ― | 4.66% | 27.83% | |
47 Neutral | kr705.90M | -5.65 | -36.55% | ― | 48.53% | 17.86% | |
43 Neutral | kr1.15B | -1.16 | -50.36% | ― | -24.97% | -366.73% |
* Healthcare Sector Average
SE:CEVI
CellaVision AB
143.60
-40.50
-22.00%
SE:BICO
BICO Group AB Class B
16.20
-19.08
-54.08%
SE:SEZI
Senzime AB
4.51
-0.38
-7.78%
SE:XVIVO
Xvivo Perfusion AB
261.00
-16.00
-5.78%
SE:CRAD.B
C-Rad AB Class B
36.90
1.61
4.56%
SE:SEDANA
Sedana Medical AB
8.15
-2.05
-20.10%
CellaVision AB Corporate Events
CellaVision Names Industry Veteran Steve Ferguson as New CEO to Drive Growth
Jun 5, 2026
CellaVision AB has appointed Steve Ferguson as its new CEO with immediate effect, succeeding Simon Østergaard, who will stay on during a transition period to ensure a smooth handover. Ferguson brings more than 25 years of biotechnology and di...
CellaVision AGM Confirms Dividend, New Chairman and Share Buyback Mandate
Apr 28, 2026
CellaVision’s annual general meeting in Lund approved the 2025 financial statements and granted discharge from liability to the board and CEO, while confirming a dividend of SEK 2.75 per share to be paid in early May. The meeting also decide...
CellaVision’s Q1 Profit Hit by EMEA Inventory Reset as New Hematology Solutions Roll Out
Apr 24, 2026
CellaVision reported a weaker first quarter of 2026, as net sales fell 14.6 percent to SEK 166 million and organic growth declined 6.6 percent, largely due to an inventory reduction by its main EMEA distribution partner and delayed public healthca...
CellaVision Names Former CEO Zlatko Rihter as Proposed New Chairman
Apr 16, 2026
CellaVision’s Nomination Committee has finalized its proposals for the 2026 Annual General Meeting, recommending a six-member board with unchanged remuneration levels and the election of former CEO Zlatko Rihter as the new chairman. The prop...
CellaVision Sets Date for First-Quarter 2026 Report and Investor Presentation
Apr 10, 2026
CellaVision AB, a Swedish-listed medtech firm, develops and sells automated microscopy and AI-based systems for blood and body fluid analysis that streamline clinical laboratory workflows and support rapid, accurate disease diagnosis. Operating th...
CellaVision Boosts Profitability and Expands Digital Microscopy Footprint
Apr 1, 2026
CellaVision reported rising net sales from SEK 723 million to SEK 759 million and an EBITDA increase from SEK 219 million to SEK 241 million, with the EBITDA margin improving from 30% to 32%, underscoring continued profitable growth. During the pe...
CellaVision Calls 2026 AGM and Proposes Dividend of SEK 2.75 per Share
Mar 25, 2026
CellaVision AB has called its Annual General Meeting for 28 April 2026 at the company’s premises in Lund, Sweden, setting out participation procedures for registered and nominee-registered shareholders, as well as rules for proxy representat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.